2-(4-(三氟甲基)吡啶-2-基)乙酸乙酯 | 1189770-53-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(4-(三氟甲基)吡啶-2-基)乙酸乙酯
• 英文名称: ethyl 2-(4-(trifluoromethyl)pyridin-2-yl)acetate
• 英文别名: (4-trifluoromethyl-pyridin-2-yl)-acetic acid ethyl ester；ethyl 2-[4-(trifluoromethyl)pyridin-2-yl]acetate
• CAS: 1189770-53-3
• 化学式: C₁₀H₁₀F₃NO₂
• 分子量: 233.19
• InChiKey: XMPHNIJIUGQZCC-UHFFFAOYSA-N

物化性质

• 沸点：
  247.5±35.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-(4-(三氟甲基)吡啶-2-基)乙酸乙酯 在 lithium hydroxide 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 lithium 2-(4-(trifluoromethyl)pyridin-2-yl)acetate
  参考文献：
  名称：

  Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

  摘要：

  Inhibition of glutaminase-1 (GLS-1) hampers the proliferation of tumor cells reliant on glutamine. Known glutaminase inhibitors have potential limitations, and in vivo exposures are potentially limited due to poor physicochemical properties. We initiated a GLS-1 inhibitor discovery program focused on optimizing physicochemical and pharmacokinetic properties, and have developed a new selective inhibitor, compound 27 (IPN60090), which is currently in phase 1 clinical trials. Compound 27 attains high oral exposures in preclinical species, with strong in vivo target engagement, and should robustly inhibit glutaminase in humans.

  DOI：

  10.1021/acs.jmedchem.0c01398
• 作为产物：
  描述：

  2-氯-4-三氟甲基吡啶 在 水 、 sodium hydride 、 lithium chloride 作用下， 以 1,4-二氧六环 、 二甲基亚砜 、 mineral oil 为溶剂， 反应 16.0h， 生成 2-(4-(三氟甲基)吡啶-2-基)乙酸乙酯
  参考文献：
  名称：

  [EN] 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS
  [FR] DÉRIVÉS DE 1-HÉTÉROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE ET LEURS UTILISATIONS À TITRE DE MODULATEURS DE PDE9A

  摘要：

  该发明涉及新型1,6-二取代吡唑吡嘧啶酮，化学式（I），其中Hc是一个单环、双环或三环杂环基团，其环成员为碳原子和至少1个，优选1个、2个或3个来自氮、氧和硫的杂原子，其以-S(O)r-的形式存在，其中r为0、1或2，所述杂环基团是或包括1个非芳香、饱和或部分不饱和的单环环，其中至少包含1个杂原子作为环成员，所述杂环基团通过所述至少包含1个杂原子作为环成员的非芳香、饱和或部分不饱和的单环环与支架相结合。根据该发明的一个方面，新化合物用于制造药物，特别是用于治疗感知、注意力、学习或记忆缺陷相关疾病的药物。新化合物还用于制造治疗阿尔茨海默病的药物。

  公开号：

  WO2009121919A1

文献信息

• 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS
  申请人：Giovannini Riccardo

  公开号：US20110184000A1

  公开（公告）日：2011-07-28

  The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with is a mono-, bi- or tri-cyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in the form of —S(O) r — with r being 0, 1 or 2, and—said heterocyclyl group is or comprises 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member and—said heterocyclyl group is bound to the scaffold by said 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.

  本发明涉及一种新型的1,6-二取代吡唑嘧啶酮（Formula (I)），其中为单、双或三环杂环基，其环成员为碳原子，至少1个，优选1、2或3个杂原子，所述杂原子选自氮、氧和硫的群体，并以—S(O)r—的形式出现，其中r为0、1或2，所述杂环基是或包含1个非芳香、饱和或部分不饱和的单环环，其中至少包含1个杂原子作为环成员，并且所述杂环基通过所述1个非芳香、饱和或部分不饱和的单环环，其中至少包含1个杂原子作为环成员，与支架结合。根据本发明的一方面，新化合物用于制造药物，特别是用于治疗感知、注意力、学习或记忆缺陷的药物。新化合物也用于制造治疗阿尔茨海默病的药物。
• NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
  申请人：GIOVANNINI Riccardo

  公开号：US20110082137A1

  公开（公告）日：2011-04-07

  The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones of formula (I), in which Hc is a tetrahydropyranyl-group and R 1 is the group V—W−*, whereby V and W independently of each other may be an aryl group or an heteroaryl group, which independently of each other may optionally be substituted. According to one aspect of the invention the new compounds are for use as medicaments or for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments and/or for use in the treatment of e.g. Alzheimer's disease, in particular for cognitive impairment associated with Alzheimer's disease.

  本发明涉及一种新型的1,6-二取代吡唑嘧啶酮化合物，其化学式为（I），其中Hc为四氢吡喃基团，R1为V-W−*基团，其中V和W各自独立地可以是芳基基团或杂环基团，可以选择地进行取代。根据本发明的一个方面，这些新化合物可用作药物或制药用途，特别是用于治疗与感知、注意力、学习或记忆缺陷有关的疾病。这些新化合物还可用于制药或用于治疗例如阿尔茨海默病等疾病，特别是用于与阿尔茨海默病相关的认知障碍的治疗。
• 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS
  申请人：GIOVANNINI Riccardo

  公开号：US20140073641A1

  公开（公告）日：2014-03-13

  The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, wherein i.) the nitrogen atom of the pyrazolo-group that is next to the pyrimidino-group is attached to a non-aromatic, organic heterocycle having at least one ring hetero atom selected from O, N and S and ii.) to the C-atom between the two nitrogen atoms of the pyrimidinone-ring a second substituent is bound via an optionally substituted methylene-bridge. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.

  本发明涉及新型1,6-二取代吡唑嘧啶酮，其中i)紧邻嘧啶基的吡唑环上的氮原子连接到至少具有一个O、N和S中的环异构原子的非芳香性有机杂环上，ii)通过可选取代的亚甲基桥连接到嘧啶酮环的两个氮原子之间的C原子上的第二个取代基。根据本发明的一个方面，新化合物用于制造药物，特别是用于治疗感知、注意力、学习或记忆缺陷的药物。新化合物还用于制造治疗阿尔茨海默病的药物。
• COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
  申请人：GIOVANNINI Riccardo

  公开号：US20140350025A1

  公开（公告）日：2014-11-27

  The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones of formula (I), in which Hc is a tetrahydropyranyl-group and R 1 is the group V—W—*, whereby V and W independently of each other may be an aryl group or an heteroaryl group, which independently of each other may optionally be substituted. According to one aspect of the invention the new compounds are for use as medicaments or for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments and/or for use in the treatment of e.g. Alzheimer's disease, in particular for cognitive impairment associated with Alzheimer's disease.

  本发明涉及新型的1,6-二取代吡唑嘧啶酮化合物，其化学式为(I)，其中Hc为四氢吡喃基团，R1为V-W-*基团，其中V和W分别可以是芳基或杂环基团，这些基团可以独立地选择是否取代。根据本发明的一方面，这些新化合物可用作药物或药物的制造，特别是用于治疗与感知、注意力、学习或记忆缺陷有关的疾病。这些新化合物还可用于制造药物和/或用于治疗阿尔茨海默病等疾病，特别是用于与阿尔茨海默病相关的认知障碍的治疗。
• GLS1 INHIBITORS FOR TREATING DISEASE
  申请人：Board of Regents, The University of Texas System

  公开号：US20160009704A1

  公开（公告）日：2016-01-14

  Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

  本文揭示了一些化合物和组合物，其结构公式为I，可用于治疗GLS1介导的疾病，如癌症。还提供了抑制人类或动物主体中GLS1活性的方法。